Last reviewed · How we verify
Qutenza — Competitive Intelligence Brief
marketed
capsaicin
Transient receptor potential cation channel subfamily V member 1
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Qutenza (CAPSAICIN) — Averitas.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Qutenza TARGET | CAPSAICIN | Averitas | marketed | capsaicin | Transient receptor potential cation channel subfamily V member 1 | 2009-01-01 |
| Cortisporin | NEOMYCIN | Pfizer | marketed | Aminoglycoside Antibacterial | Transient receptor potential cation channel subfamily V member 1 | 1957-01-01 |
| Neomycin B | FRAMYCETIN | phase 3 | framycetin | Lecithin retinol acyltransferase, Menin, Transient receptor potential cation channel subfamily V member 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (capsaicin class)
- Averitas · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Qutenza CI watch — RSS
- Qutenza CI watch — Atom
- Qutenza CI watch — JSON
- Qutenza alone — RSS
- Whole capsaicin class — RSS
Cite this brief
Drug Landscape (2026). Qutenza — Competitive Intelligence Brief. https://druglandscape.com/ci/capsaicin. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab